RT Journal Article
T1 Per- and polyfluoroalkyl substances (PFASs) modify lung surfactant function and pro-inflammatory responses in human bronchial epithelial cells
A1 Sørli, Jorid B.
A1 Låg, Marit
A1 Ekerenb, Leni
A1 Pérez-Gil, Jesús
A1 Haug, Line S. H
A1 Da Silva, Emilie
A1 Matrod, Muhammad N.
A1 Gützkow, Kristine B.
A1 Lindeman, Birgitte
AB The toxicity of some per- and polyfluoroalkyl substances (PFASs), such as perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) has been studied thoroughly, showing that systemic PFASs targets the lungs. However, regulators lack data to assess the impact of other PFASs on the lungs and alternative methods to test substances for lung toxicity are needed. We combined two in vitro models to assess toxicity to the respiratory system; i) a lung surfactant (LS) function assay to assess the acute inhalation toxicity potential, and ii) a cell model with human bronchial epithelial cells to study pro-inflammatory potential and modulation of inflammatory responses. We tested salts of four PFASs: perfluorobutane sulfonate (PFBS), perfluorohexane sulfonate (PFHxS), PFOS, and PFOA as well as the fluorotelomer 8:2 FTOH. The results show that PFHxS, PFOA and PFOS can inhibit LS function. High PFOS concentrations induced a pro-inflammatory response, measured as increased IL-1α/β release. Moderate concentrations of PFOS suppressed release of the chemokines CXCL8 and CXCL10, whereas both PFOS and PFOA stimulated the release of the pro-inflammatory cytokine IL-1β in immune stimulated human bronchial epithelial cells. These findings support the concern that some PFASs may increase the risk of acute lung toxicity and of airway infections.
PB Elsevier
SN 0887-2333, ESSN: 1879-3177
YR 2020
FD 2020-02
LK https://hdl.handle.net/20.500.14352/5962
UL https://hdl.handle.net/20.500.14352/5962
LA eng
NO Ministerio de Ciencia e Innovación (MICINN)
NO Comunidad de Madrid
NO Norwegian Environment Agency
DS Docta Complutense
RD 9 abr 2025